Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt's higher-dose Pennsaid gets 2nd FDA look, as firm faces lawsuit

This article was originally published in Scrip

Executive Summary

A day after Mallinckrodt Pharmaceuticals' partner filed a lawsuit in the US District Court for the Southern District of New York against the firm asserting breach of contract involving its Pennsaid (diclofenac sodium topical solution) products, the company said the FDA had accepted its resubmitted new drug application (NDA) for the 2% formulation of the non-steroidal anti-inflammatory drug, which previously went under the moniker MNK-395.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel